Back to search

Article

The costimulatory domain influences CD19 CAR-T cell resistance development in B-cell malignancies

2025-03-05

Abstract excerpt

CD19-CAR-T-cells emerge as a major therapeutic option for relapsed/refractory B-cell-derived malignancies, however approximately half of patients eventually relapse. To identify resistance-driving factors, we repeatedly exposed B-cell lymphoma/B-cell acute lymphoblastic leukemia to 4-1BB/CD28-based CD19-CAR-T-cells in vitro . Generated models revealed costimulatory domain-dependent differences in CD19 loss. While...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1c4cfe55-4a03-59d2-a6b4-b4607a204cbc
DOI
10.1101/2025.02.28.640707
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The costimulatory domain influences CD19 CAR-T cell resistance development in B-cell malignanciesDOI 10.1101/2025.02.28.640707
Computational modeling and optimization of peptide-based CAR-T cell receptors targeting CD19 for enhanced efficacy and minimized toxicitySemantic proximity
Genomic drivers of large B-cell lymphoma resistance to CD19 CAR-T therapySemantic proximity
Sequential Antigen-loss and Branching Evolution in Lymphoma after Anti-CD19 and Anti-CD20 Targeted T Cell Redirecting ImmunotherapySemantic proximity
The CD19 CAR T hinge region influences avidity and cytotoxicity in CD19 SNP variants in B-cell LymphomaSemantic proximity
In silico and in vivo analysis reveal impact of c-Myc tag in FMC63 scFv-CD19 protein interface and CAR-T cell efficacySemantic proximity
High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling <i>CD19</i> splicing and CART-19 therapy resistanceSemantic proximity
Balancing activation and costimulation of CAR tunes signaling dynamics and enhances therapeutic potencySemantic proximity
Chimeric antigen receptor-modified T cells strike backSemantic proximity
Fine Epitope Mapping of the CD19 Extracellular Domain Promotes Design.Semantic proximity
Computational structural optimization enhances IL13Rα2 – B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escapeSemantic proximity
A 68Ga–BCMA Ectodomain Tracer Enables PET/MR Longitudinal Tracking of Clinical-Grade BCMA/CD19 CAR T CellsSemantic proximity
CARPOOL: A library-based platform to rapidly identify next generation chimeric antigen receptorsSemantic proximity
Select a neighboring publication to make it the new centre.